ENOV Stock Analysis: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$22.50
2.46 (12.28%)
▲
5d:
+2.23%
30d:
+2.55%
90d:
-3.72%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ENOV shows positive signals but monitor for confirmation. Market pricing in 5.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ENOV shows positive signals but monitor for confirmation. Market pricing in 5.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.59
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$23.96
6.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $22.50, which is considered oversold relative to its 30-day fair value range of $21.18 to $23.30. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.5) compared to its historical average (6.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.2% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is showing sideways momentum. The price is approaching resistance at $22.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: ENOV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $42.30 (+88.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENOV is showing sideways momentum. The price is approaching resistance at $22.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: ENOV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $42.30 (+88.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.18 -
$23.30
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.3%)
- BULLISH: Trading 88.0% below Wall St target ($42.30)
Trading Range Analysis
30-Day Trading Range
$21.18 -
$23.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.14
Resistance Level
$22.71
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.52
Wall Street Target
$42.30
(+88.0%)
Revenue Growth (YoY)
5.4%
Earnings Growth (YoY)
153.1%
Profit Margin
-49.9%
Valuation Discount vs History
-5.2% cheaper
PE vs Historical
5.5 vs 6.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.2%
(market-implied from PE analysis)
1-Year Target
$21.33
(-5%)
2-Year Target
$20.22
(-10%)
3-Year Target
$19.17
(-15%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$22.57
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 11.7%)
$123.58
(+449%)
Base:
(SPY PE: 5.5, Growth: 11.7%)
$31.33
(+39%)
Bear:
(PE: 4.7, Growth: 11.7%)
$26.63
(+18%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.5 to 6.5
Stabilization Target:
$26.49
(+17.7%)
PE Expansion Potential:
+17.7%
Share & Embed Analysis
Last updated: July 03, 2026 8:58 PM ET
Data refreshes hourly during market hours. Next update: 9:58 PM
Data refreshes hourly during market hours. Next update: 9:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Oliver Engert
BUY
1000 shares
2026-03-13
Oliver Engert
BUY
1000 shares
2026-03-09
Oliver Engert
BUY
750 shares
2026-03-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
